Literature DB >> 12960133

Disparity of sensitivities in detection of radiation-naïve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2.

Sing-Fai Leung1, Y M Dennis Lo, Anthony T C Chan, Kai-Fai To, Edward To, Lisa Y S Chan, Benny Zee, Dolly P Huang, Philip J Johnson.   

Abstract

PURPOSE: The purpose of this research was to compare the sensitivities of plasma EBV DNA in detection of postirradiation locally recurrent nasopharyngeal carcinoma (NPC), postirradiation distant metastatic NPC, and radiation-naïve NPC. EXPERIMENTAL
DESIGN: Twenty-four patients with postirradiation local recurrence of NPC were assessed for plasma EBV DNA levels by a real-time quantitative PCR system. The results were compared with those of a cohort of 140 patients with newly diagnosed NPC and with those of 25 patients with distant metastatic relapse. EBV-encoded RNA positivity was also assessed in locally recurrent tumors and newly diagnosed tumors with undetectable plasma EBV DNA levels.
RESULTS: Postirradiation locally recurrent tumors were associated with a significantly lower rate of detectable plasma EBV DNA compared with radiation-naïve tumors of comparable stage [stage I-II tumors: 5 of 12 (42%) versus 47 of 51 (92%), P = 0.0002; stage III-IV tumors: 10 of 12 (83%) versus 88 of 89 (99%), P = 0.01; Fisher's exact test], and compared with distant metastatic recurrences [15 of 24 (63%) versus 24 of 25 (96%), P < 0.02; Fisher's exact test]. The median EBV DNA level in patients with detectable EBV DNA was also significantly lower in locally recurrent tumors than in radiation-naïve tumors. All of the tissue samples of tumors associated with undetectable EBV DNA levels, where available, were EBV-encoded RNA positive.
CONCLUSIONS: The sensitivity of EBV DNA in the detection of tumors regrowing from an irradiated site is much lower than that from a radiation-naïve site. Although plasma EBV DNA is very effective in detecting distant metastatic relapse of NPC, it cannot be relied on as the sole surveillance tool for detection of local relapse.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960133

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

Review 1.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  [Development and validation of a multivariate risk model for distant metastasis of advanced nasopharyngeal carcinoma].

Authors:  Lu Zhang; Xiaoning Luo; Xiaokai Mo; Wenhui Huang; Changhong Liang; Shuixing Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-12-30

3.  Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia.

Authors:  Servi J C Stevens; Sandra A W M Verkuijlen; Bambang Hariwiyanto; Jajah Fachiroh; Dewi K Paramita; I Bing Tan; Sophia M Haryana; Jaap M Middeldorp
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

4.  Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma.

Authors:  Fei-Peng Zhao; Xiong Liu; Xiao-Mei Chen; Juan Lu; Bo-Long Yu; Wen-Dong Tian; L U Wang; Xia Xu; Hao-Ran Huang; Meng-Wen Zhang; Gang Li; Xiang-Ping Li
Journal:  Oncol Lett       Date:  2015-08-24       Impact factor: 2.967

5.  The association between circulating tumor cells and Epstein-Barr virus activation in patients with nasopharyngeal carcinoma.

Authors:  Caiyun He; Xinjun Huang; Xuan Su; Tao Tang; Xiao Zhang; Jiangjun Ma; Xiang Guo; Xing Lv
Journal:  Cancer Biol Ther       Date:  2017-01-25       Impact factor: 4.742

6.  Deep learning signatures reveal multiscale intratumor heterogeneity associated with biological functions and survival in recurrent nasopharyngeal carcinoma.

Authors:  Xun Zhao; Yu-Jing Liang; Xu Zhang; Dong-Xiang Wen; Wei Fan; Lin-Quan Tang; Di Dong; Jie Tian; Hai-Qiang Mai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-26       Impact factor: 10.057

7.  Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.

Authors:  J S Kalpoe; P B Douwes Dekker; J H J M van Krieken; R J Baatenburg de Jong; A C M Kroes
Journal:  J Clin Pathol       Date:  2006-02-17       Impact factor: 3.411

Review 8.  Update on molecular diagnostic tests in head and neck cancer.

Authors:  Kevin T Palka; Robbert J Slebos; Christine H Chung
Journal:  Semin Oncol       Date:  2008-06       Impact factor: 4.929

Review 9.  Laboratory assays for Epstein-Barr virus-related disease.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

10.  The impact of plasma Epstein-Barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study.

Authors:  L-Q Tang; Q-Y Chen; S-S Guo; W-H Chen; C-F Li; L Zhang; X-P Lai; Y He; Y-X-X Xu; D-P Hu; S-H Wen; Y-T Peng; H Liu; L-T Liu; S-M Yan; L Guo; C Zhao; K-J Cao; Q Liu; C-N Qian; J Ma; X Guo; M-S Zeng; H-Q Mai
Journal:  Br J Cancer       Date:  2014-07-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.